Feb 12 (Reuters) - Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...

Eli Lilly and Co. has signed a deal worth up to $1.12 billion with Dresden, Germany-based-based Seamless Therapeutics to develop and commercialize treatments for hearing loss using the German ...

Jan 28 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and ...

FAIRPORT, N.Y. — Meet Lily, a horse from Lollypop Farm who is looking for a home. The 24-year-old Thoroughbred horse feels comfortable with her people and environment. Once Lily meets new people and ...

The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if not sooner, investors will begin to worry about Eli Lilly ...